Rasio cepet ACADIA Pharmaceuticals (ACAD)

The neuropreparation market demonstrates high resilience to macroeconomic factors. ACADIA Pharmaceuticals (ACAD) dominates the treatment of Parkinson's disease psychosis thanks to a unique product with no equivalents. Growth is supported by the expansion of Daybue indications and strict control of R&D costs. The prompt coverage of current liabilities clearly illustrates financial stability, and the value of 3.46 captures this metric.

Quick liquidity measures a company's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding slow-moving inventories. For the biopharmaceutical business of ACADIA (ACAD), where laboratory waste disposal and energy saving costs are fixed, this ratio of cash and receivables to short-term debt confirms capital resilience against potential cash flow gaps.